{"gene":"UAP1","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2023,"finding":"UAP1 (UDP-N-acetylglucosamine pyrophosphorylase 1) functions as a protein pyrophosphorylase, directly catalyzing serine pyrophosphorylation of IRF3 at Ser386, thereby promoting robust type I interferon responses. Uap1-deficient mice showed impaired DNA- and RNA-virus-induced type I IFN pathways and were highly susceptible to lethal viral infection.","method":"Biochemical identification of pyrophosphorylase activity, Uap1 knockout mice (loss-of-function), viral infection models, IRF3 phosphorylation assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO with defined immune phenotype, identification of specific substrate (IRF3 Ser386), enzymatic activity characterization, multiple orthogonal methods","pmids":["36603579"],"is_preprint":false},{"year":2014,"finding":"UAP1 overexpression in prostate cancer cells increases intracellular UDP-GlcNAc levels ~10-fold and confers resistance to inhibitors of N-linked glycosylation (tunicamycin and 2-deoxyglucose), but not to a general ER stress inducer (calcium ionophore A23187). UAP1 knockdown re-sensitized cells to N-linked glycosylation inhibitors as measured by proliferation and ER stress marker activation.","method":"UAP1 knockdown (siRNA/shRNA), cell proliferation assays, ER stress marker detection, UDP-GlcNAc quantification, tissue microarray","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific phenotypic readout and metabolite quantification, single lab with two orthogonal readouts","pmids":["25241896"],"is_preprint":false},{"year":2020,"finding":"A de novo missense mutation in UAP1 (p.A229T) decreases the stability and enzymatic activity of the AGX1 isoform in vitro. X-ray crystallography revealed a structural shift proximal to the mutation site leading to a conformational change of the N-terminal domain, suggesting this mutation is pathogenic and relevant to the patient's intellectual disability phenotype.","method":"In vitro enzymatic activity assay, X-ray crystallography, site-directed mutagenesis (patient-derived variant)","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional validation (in vitro activity assay), mechanistic link between mutation and structural change established in one rigorous study","pmids":["33098688"],"is_preprint":false},{"year":2012,"finding":"Human AGX1 (UAP1 isoform) catalyzes synthesis of UDP-N-acetylgalactosamine from N-acetylgalactosamine-1-phosphate and UTP via uridyltransfer reaction. The enzyme also accepts dUTP and dTTP as substrates, enabling synthesis of dUDP-GalNAc and dTDP-GalNAc in vitro.","method":"In vitro enzymatic assay with systematic nucleotide substrate specificity profiling","journal":"Bioorganic & medicinal chemistry letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro reconstitution of enzymatic activity, single lab, single method","pmids":["22595178"],"is_preprint":false},{"year":2025,"finding":"The NSUN2/SRSF6/UAP1 signaling axis regulates multidrug resistance in anaplastic thyroid cancer. NSUN2 methylates SRSF6 mRNA (m5C modification, read by ALYREF), which redirects UAP1 alternative splicing from the AGX1 to the AGX2 splice form. AGX2 enhances N-linked glycosylation of ABC transporters, stabilizing them by preventing ubiquitination-mediated degradation.","method":"NSUN2 knockout cell lines, MeRIP-seq, transcriptomic and proteomic analyses, alternative splicing analysis, glycoprotein staining, denaturing IP ubiquitination assay, nuclear-cytoplasmic fractionation, PCR","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (MeRIP-seq, proteomics, ubiquitination IP, splicing analysis) in single lab establishing pathway mechanism","pmids":["40083919"],"is_preprint":false},{"year":1998,"finding":"SPAG2 (UAP1 alias) protein is localized to the outer dense fibers (ODFs) of the human sperm flagellum, as determined by immunofluorescence of Triton X-100-extracted spermatozoa and electron microscopy. SPAG2 does not share sequence homology with known ODF keratin-like intermediate filament proteins, representing a novel ODF component.","method":"Immunofluorescence microscopy, electron microscopy, in situ hybridization (cDNA library screening)","journal":"Molecular reproduction and development","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct subcellular localization by immunofluorescence and EM, two orthogonal microscopy methods, single lab","pmids":["9621304"],"is_preprint":false},{"year":2020,"finding":"UAP1 silencing in bladder cancer cell lines led to reduction in proliferation, invasion, colony formation, and migration, establishing a functional role for UAP1 in supporting bladder cancer cell aggressiveness.","method":"siRNA-mediated UAP1 knockdown, proliferation assay, invasion assay, colony formation assay, migration assay","journal":"Genes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with multiple specific phenotypic readouts, single lab","pmids":["32650368"],"is_preprint":false},{"year":2025,"finding":"CRISPR-Cas9 knockout of UAP1 in lung cancer cell lines significantly reduced aggressive behaviors (proliferation, colony formation, migration, invasion) and reduced N-linked glycosylation levels, mediated through cell cycle regulators (cyclin D1, p21, XIAP) and EMT markers (E-cadherin, vimentin, slug, snail).","method":"CRISPR-Cas9 knockout, lectin blot (Con A and PHA-E), MTT assay, Boyden chamber assay, molecular shift assay for GP130","journal":"Glycobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with multiple phenotypic readouts and glycosylation biochemistry, single lab","pmids":["41452006"],"is_preprint":false}],"current_model":"UAP1 (also known as AGX1/SPAG2) is the terminal enzyme of the hexosamine biosynthetic pathway, catalyzing UDP-N-acetylhexosamine (UDP-GlcNAc/UDP-GalNAc) synthesis from NTP and N-acetylhexosamine-1-phosphate; beyond this canonical metabolic role, UAP1 has been identified as a protein pyrophosphorylase that directly catalyzes Ser386 pyrophosphorylation of IRF3 to drive innate antiviral type I IFN responses, and its two splice isoforms (AGX1 and AGX2) are subject to alternative splicing regulation via the NSUN2/SRSF6 axis, with the AGX2 isoform specifically enhancing N-linked glycosylation of ABC transporters to promote drug resistance."},"narrative":{"mechanistic_narrative":"UAP1 is the terminal enzyme of the hexosamine biosynthetic pathway, catalyzing the uridyltransfer reaction that produces UDP-N-acetylhexosamines from N-acetylhexosamine-1-phosphate and a nucleotide triphosphate, with the AGX1 isoform accepting UTP, dUTP, and dTTP to generate UDP-/dUDP-/dTDP-GalNAc in vitro [PMID:22595178]. By supplying UDP-GlcNAc as the donor for N-linked glycosylation, UAP1 supports cellular proliferation and stress resistance: overexpression raises intracellular UDP-GlcNAc roughly ten-fold and confers resistance to N-linked glycosylation inhibitors, while knockdown re-sensitizes cells and triggers ER stress [PMID:25241896]. Through this glycosylation-supporting activity UAP1 promotes the aggressive behavior of multiple cancers, where its loss reduces proliferation, migration, invasion, and N-linked glycosylation and shifts cell-cycle and EMT regulators [PMID:32650368, PMID:41452006]. Beyond metabolism, UAP1 acts as a protein pyrophosphorylase that directly pyrophosphorylates IRF3 at Ser386 to drive robust type I interferon responses, with Uap1-deficient mice showing impaired antiviral IFN signaling and lethal susceptibility to DNA- and RNA-virus infection [PMID:36603579]. A de novo p.A229T missense mutation that destabilizes the AGX1 isoform and alters its N-terminal domain conformation links UAP1 to an intellectual disability phenotype [PMID:33098688].","teleology":[{"year":1998,"claim":"Before any enzymatic role was assigned, the protein (as SPAG2) was placed at a discrete subcellular structure, establishing its presence as a novel non-intermediate-filament component of the sperm flagellar outer dense fibers.","evidence":"Immunofluorescence and electron microscopy of Triton-extracted spermatozoa, plus cDNA library screening","pmids":["9621304"],"confidence":"Medium","gaps":["No functional consequence of ODF localization established","Relationship between this structural localization and the later-defined enzymatic activity unexplored"]},{"year":2012,"claim":"The core biochemical activity was defined by reconstituting AGX1 as a uridyltransferase that synthesizes UDP-GalNAc and, unexpectedly, accepts deoxynucleotide substrates, mapping its substrate scope.","evidence":"In vitro enzymatic assay with systematic nucleotide substrate specificity profiling","pmids":["22595178"],"confidence":"Medium","gaps":["In vitro substrate promiscuity (dUTP/dTTP) of unknown physiological relevance","No structural basis for substrate selection","Single lab, single method"]},{"year":2014,"claim":"The metabolic output was linked to a cellular phenotype, showing that UAP1-driven UDP-GlcNAc supply sustains N-linked glycosylation and protects cancer cells from glycosylation-inhibitor-induced ER stress.","evidence":"siRNA/shRNA knockdown with proliferation and ER stress readouts, UDP-GlcNAc quantification, tissue microarray in prostate cancer cells","pmids":["25241896"],"confidence":"Medium","gaps":["Specific glycoprotein clients not identified","Resistance shown only against glycosylation inhibitors, not general ER stress"]},{"year":2020,"claim":"A disease-causing variant was characterized structurally and functionally, establishing that destabilization of the AGX1 isoform via a conformational shift in the N-terminal domain can produce a Mendelian neurodevelopmental phenotype.","evidence":"In vitro activity assay, X-ray crystallography, and site-directed mutagenesis of a patient-derived p.A229T variant","pmids":["33098688"],"confidence":"High","gaps":["Causality at the organismal level not tested (no animal model of the variant)","Mechanistic connection between reduced enzymatic activity and intellectual disability not resolved"]},{"year":2020,"claim":"The pro-tumorigenic role was extended beyond prostate to bladder cancer, generalizing UAP1 as a supporter of cancer-cell aggressiveness.","evidence":"siRNA knockdown with proliferation, invasion, colony formation, and migration assays in bladder cancer cell lines","pmids":["32650368"],"confidence":"Medium","gaps":["Molecular mediators not defined in this system","No in vivo validation"]},{"year":2023,"claim":"A non-canonical catalytic function was discovered: UAP1 acts as a protein pyrophosphorylase on IRF3 Ser386, revealing a direct enzymatic role in innate antiviral immunity distinct from its metabolic activity.","evidence":"Biochemical pyrophosphorylase assay, Uap1 knockout mice, viral infection models, IRF3 phosphorylation assays","pmids":["36603579"],"confidence":"High","gaps":["How the same enzyme partitions between sugar-nucleotide synthesis and protein pyrophosphorylation is unresolved","Substrate scope of the pyrophosphorylase activity beyond IRF3 unknown"]},{"year":2025,"claim":"Isoform-specific regulation was placed in a signaling axis, showing that NSUN2/SRSF6-controlled alternative splicing toward AGX2 enhances ABC-transporter glycosylation and stability to drive multidrug resistance.","evidence":"NSUN2 knockout cells, MeRIP-seq, proteomics, splicing analysis, glycoprotein staining, and denaturing ubiquitination IP in anaplastic thyroid cancer; CRISPR-Cas9 UAP1 knockout with lectin blots in lung cancer","pmids":["40083919","41452006"],"confidence":"Medium","gaps":["Functional difference between AGX1 and AGX2 at the enzymatic level not fully defined","Direct interaction of AGX2 with ABC transporters not demonstrated","Single lab for the thyroid axis"]},{"year":null,"claim":"It remains unknown how UAP1 mechanistically toggles between its sugar-nucleotide pyrophosphorylase metabolic role, its IRF3 protein-pyrophosphorylase immune role, and its isoform-specific glycosylation-promoting role in disease.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural or regulatory model linking the metabolic and protein-pyrophosphorylase activities","Cellular determinants of AGX1 vs AGX2 functional specialization undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[3]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,3]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,7]}],"complexes":[],"partners":["IRF3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16222","full_name":"UDP-N-acetylhexosamine pyrophosphorylase","aliases":["Antigen X","AGX","Protein-pyrophosphorylation enzyme","Sperm-associated antigen 2","UDP-N-acetylgalactosamine pyrophosphorylase","UDP-N-acetylglucosamine pyrophosphorylase"],"length_aa":522,"mass_kda":58.8,"function":"Catalyzes the last step in biosynthesis of uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) by converting UTP and glucosamine 1-phosphate (GlcNAc-1-P) to the sugar nucleotide (PubMed:9603950, PubMed:9765219). Also converts UTP and galactosamine 1-phosphate (GalNAc-1-P) into uridine diphosphate-N-acetylgalactosamine (UDP-GalNAc) (PubMed:9765219). In addition to its role in metabolism, acts as a regulator of innate immunity in response to virus infection by mediating pyrophosphorylation of IRF3: catalyzes pyrophosphorylation of IRF3 phosphorylated at 'Ser-386' by TBK1, promoting IRF3 dimerization and activation, leading to type I interferon responses (PubMed:36603579) Isoform AGX1 has 2 to 3 times higher activity towards galactosamine 1-phosphate (GalNAc-1-P) Isoform AGX2 has 8 times more activity towards glucosamine 1-phosphate (GlcNAc-1-P)","subcellular_location":"Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/Q16222/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/UAP1","classification":"Not Classified","n_dependent_lines":270,"n_total_lines":1208,"dependency_fraction":0.22350993377483444},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/UAP1","total_profiled":1310},"omim":[{"mim_id":"602862","title":"UDP-N-ACETYLGLUCOSAMINE PYROPHOSPHORYLASE 1; UAP1","url":"https://www.omim.org/entry/602862"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":93.9}],"url":"https://www.proteinatlas.org/search/UAP1"},"hgnc":{"alias_symbol":["AGX1","AgX"],"prev_symbol":["SPAG2"]},"alphafold":{"accession":"Q16222","domains":[{"cath_id":"-","chopping":"4-40","consensus_level":"medium","plddt":96.8962,"start":4,"end":40},{"cath_id":"3.90.550.10","chopping":"44-417","consensus_level":"high","plddt":95.9045,"start":44,"end":417},{"cath_id":"2.10.10.100","chopping":"439-455_471-517","consensus_level":"high","plddt":89.6248,"start":439,"end":517}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16222","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16222-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16222-F1-predicted_aligned_error_v6.png","plddt_mean":93.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=UAP1","jax_strain_url":"https://www.jax.org/strain/search?query=UAP1"},"sequence":{"accession":"Q16222","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16222.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16222/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16222"}},"corpus_meta":[{"pmid":"25241896","id":"PMC_25241896","title":"UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25241896","citation_count":80,"is_preprint":false},{"pmid":"24754894","id":"PMC_24754894","title":"Dual responsive enzyme mimicking activity of AgX (X=Cl, Br, I) nanoparticles and its application for cancer cell detection.","date":"2014","source":"ACS applied materials & interfaces","url":"https://pubmed.ncbi.nlm.nih.gov/24754894","citation_count":77,"is_preprint":false},{"pmid":"25399020","id":"PMC_25399020","title":"Functional inactivation of UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1) induces early leaf senescence and defence responses in rice.","date":"2014","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/25399020","citation_count":72,"is_preprint":false},{"pmid":"28967675","id":"PMC_28967675","title":"Excessive UDPG resulting from the mutation of UAP1 causes programmed cell death by triggering reactive oxygen species accumulation and caspase-like activity in rice.","date":"2017","source":"The New phytologist","url":"https://pubmed.ncbi.nlm.nih.gov/28967675","citation_count":40,"is_preprint":false},{"pmid":"40083919","id":"PMC_40083919","title":"NSUN2-mediated m5C modification drives alternative splicing reprogramming and promotes multidrug resistance in anaplastic thyroid cancer through the NSUN2/SRSF6/UAP1 signaling axis.","date":"2025","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/40083919","citation_count":28,"is_preprint":false},{"pmid":"14745783","id":"PMC_14745783","title":"Alanine : glyoxylate aminotransferase of Saccharomyces cerevisiae-encoding gene AGX1 and metabolic significance.","date":"2004","source":"Yeast (Chichester, England)","url":"https://pubmed.ncbi.nlm.nih.gov/14745783","citation_count":26,"is_preprint":false},{"pmid":"36603579","id":"PMC_36603579","title":"Metabolic enzyme UAP1 mediates IRF3 pyrophosphorylation to facilitate innate immune response.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/36603579","citation_count":21,"is_preprint":false},{"pmid":"9621304","id":"PMC_9621304","title":"Expression of the human antigen SPAG2 in the testis and localization to the outer dense fibers in spermatozoa.","date":"1998","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/9621304","citation_count":17,"is_preprint":false},{"pmid":"33269005","id":"PMC_33269005","title":"Expression and Bioinformatics-Based Functional Analysis of UAP1 in Lung Adenocarcinoma.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/33269005","citation_count":13,"is_preprint":false},{"pmid":"32650368","id":"PMC_32650368","title":"Quantitative Proteomics of Urinary Bladder Cancer Cell Lines Identify UAP1 as a Potential Therapeutic Target.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32650368","citation_count":12,"is_preprint":false},{"pmid":"30620168","id":"PMC_30620168","title":"Fe Foil-Guided Fabrication of Uniform Ag@AgX Nanowires for Sensitive Detection of Leukemia DNA.","date":"2019","source":"ACS applied materials & interfaces","url":"https://pubmed.ncbi.nlm.nih.gov/30620168","citation_count":8,"is_preprint":false},{"pmid":"34249055","id":"PMC_34249055","title":"UDP-N-Acetylglucosamine Pyrophosphorylase 2 (UAP2) and 1 (UAP1) Perform Synergetic Functions for Leaf Survival in Rice.","date":"2021","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/34249055","citation_count":7,"is_preprint":false},{"pmid":"22595178","id":"PMC_22595178","title":"Investigation of the nucleotide triphosphate substrate specificity of Homo sapiens UDP-N-acetylgalactosamine pyrophosphorylase (AGX1).","date":"2012","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/22595178","citation_count":6,"is_preprint":false},{"pmid":"33098688","id":"PMC_33098688","title":"A missense mutation in a patient with developmental delay affects the activity and structure of the hexosamine biosynthetic pathway enzyme AGX1.","date":"2020","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/33098688","citation_count":5,"is_preprint":false},{"pmid":"41452006","id":"PMC_41452006","title":"High glucose enhances lung cancer cell aggressiveness: the impacts of GLUT1, UAP1, UGP2, and N-linked glycosylation.","date":"2025","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/41452006","citation_count":1,"is_preprint":false},{"pmid":"34008948","id":"PMC_34008948","title":"Stretchable AgX (X = Se, Te) for Efficient Thermoelectrics and Photovoltaics.","date":"2021","source":"ACS applied materials & interfaces","url":"https://pubmed.ncbi.nlm.nih.gov/34008948","citation_count":1,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.10.14.618283","title":"The Hexosamine Biosynthetic Pathway alters the cytoskeleton to modulate cell proliferation and migration in metastatic prostate cancer","date":"2024-10-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.14.618283","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":10608,"output_tokens":2153,"usd":0.032059,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9179,"output_tokens":2917,"usd":0.05941,"stage2_stop_reason":"end_turn"},"total_usd":0.091469,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2023,\n      \"finding\": \"UAP1 (UDP-N-acetylglucosamine pyrophosphorylase 1) functions as a protein pyrophosphorylase, directly catalyzing serine pyrophosphorylation of IRF3 at Ser386, thereby promoting robust type I interferon responses. Uap1-deficient mice showed impaired DNA- and RNA-virus-induced type I IFN pathways and were highly susceptible to lethal viral infection.\",\n      \"method\": \"Biochemical identification of pyrophosphorylase activity, Uap1 knockout mice (loss-of-function), viral infection models, IRF3 phosphorylation assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO with defined immune phenotype, identification of specific substrate (IRF3 Ser386), enzymatic activity characterization, multiple orthogonal methods\",\n      \"pmids\": [\"36603579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"UAP1 overexpression in prostate cancer cells increases intracellular UDP-GlcNAc levels ~10-fold and confers resistance to inhibitors of N-linked glycosylation (tunicamycin and 2-deoxyglucose), but not to a general ER stress inducer (calcium ionophore A23187). UAP1 knockdown re-sensitized cells to N-linked glycosylation inhibitors as measured by proliferation and ER stress marker activation.\",\n      \"method\": \"UAP1 knockdown (siRNA/shRNA), cell proliferation assays, ER stress marker detection, UDP-GlcNAc quantification, tissue microarray\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific phenotypic readout and metabolite quantification, single lab with two orthogonal readouts\",\n      \"pmids\": [\"25241896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A de novo missense mutation in UAP1 (p.A229T) decreases the stability and enzymatic activity of the AGX1 isoform in vitro. X-ray crystallography revealed a structural shift proximal to the mutation site leading to a conformational change of the N-terminal domain, suggesting this mutation is pathogenic and relevant to the patient's intellectual disability phenotype.\",\n      \"method\": \"In vitro enzymatic activity assay, X-ray crystallography, site-directed mutagenesis (patient-derived variant)\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional validation (in vitro activity assay), mechanistic link between mutation and structural change established in one rigorous study\",\n      \"pmids\": [\"33098688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Human AGX1 (UAP1 isoform) catalyzes synthesis of UDP-N-acetylgalactosamine from N-acetylgalactosamine-1-phosphate and UTP via uridyltransfer reaction. The enzyme also accepts dUTP and dTTP as substrates, enabling synthesis of dUDP-GalNAc and dTDP-GalNAc in vitro.\",\n      \"method\": \"In vitro enzymatic assay with systematic nucleotide substrate specificity profiling\",\n      \"journal\": \"Bioorganic & medicinal chemistry letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro reconstitution of enzymatic activity, single lab, single method\",\n      \"pmids\": [\"22595178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The NSUN2/SRSF6/UAP1 signaling axis regulates multidrug resistance in anaplastic thyroid cancer. NSUN2 methylates SRSF6 mRNA (m5C modification, read by ALYREF), which redirects UAP1 alternative splicing from the AGX1 to the AGX2 splice form. AGX2 enhances N-linked glycosylation of ABC transporters, stabilizing them by preventing ubiquitination-mediated degradation.\",\n      \"method\": \"NSUN2 knockout cell lines, MeRIP-seq, transcriptomic and proteomic analyses, alternative splicing analysis, glycoprotein staining, denaturing IP ubiquitination assay, nuclear-cytoplasmic fractionation, PCR\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (MeRIP-seq, proteomics, ubiquitination IP, splicing analysis) in single lab establishing pathway mechanism\",\n      \"pmids\": [\"40083919\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"SPAG2 (UAP1 alias) protein is localized to the outer dense fibers (ODFs) of the human sperm flagellum, as determined by immunofluorescence of Triton X-100-extracted spermatozoa and electron microscopy. SPAG2 does not share sequence homology with known ODF keratin-like intermediate filament proteins, representing a novel ODF component.\",\n      \"method\": \"Immunofluorescence microscopy, electron microscopy, in situ hybridization (cDNA library screening)\",\n      \"journal\": \"Molecular reproduction and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct subcellular localization by immunofluorescence and EM, two orthogonal microscopy methods, single lab\",\n      \"pmids\": [\"9621304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"UAP1 silencing in bladder cancer cell lines led to reduction in proliferation, invasion, colony formation, and migration, establishing a functional role for UAP1 in supporting bladder cancer cell aggressiveness.\",\n      \"method\": \"siRNA-mediated UAP1 knockdown, proliferation assay, invasion assay, colony formation assay, migration assay\",\n      \"journal\": \"Genes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with multiple specific phenotypic readouts, single lab\",\n      \"pmids\": [\"32650368\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CRISPR-Cas9 knockout of UAP1 in lung cancer cell lines significantly reduced aggressive behaviors (proliferation, colony formation, migration, invasion) and reduced N-linked glycosylation levels, mediated through cell cycle regulators (cyclin D1, p21, XIAP) and EMT markers (E-cadherin, vimentin, slug, snail).\",\n      \"method\": \"CRISPR-Cas9 knockout, lectin blot (Con A and PHA-E), MTT assay, Boyden chamber assay, molecular shift assay for GP130\",\n      \"journal\": \"Glycobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with multiple phenotypic readouts and glycosylation biochemistry, single lab\",\n      \"pmids\": [\"41452006\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"UAP1 (also known as AGX1/SPAG2) is the terminal enzyme of the hexosamine biosynthetic pathway, catalyzing UDP-N-acetylhexosamine (UDP-GlcNAc/UDP-GalNAc) synthesis from NTP and N-acetylhexosamine-1-phosphate; beyond this canonical metabolic role, UAP1 has been identified as a protein pyrophosphorylase that directly catalyzes Ser386 pyrophosphorylation of IRF3 to drive innate antiviral type I IFN responses, and its two splice isoforms (AGX1 and AGX2) are subject to alternative splicing regulation via the NSUN2/SRSF6 axis, with the AGX2 isoform specifically enhancing N-linked glycosylation of ABC transporters to promote drug resistance.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"UAP1 is the terminal enzyme of the hexosamine biosynthetic pathway, catalyzing the uridyltransfer reaction that produces UDP-N-acetylhexosamines from N-acetylhexosamine-1-phosphate and a nucleotide triphosphate, with the AGX1 isoform accepting UTP, dUTP, and dTTP to generate UDP-/dUDP-/dTDP-GalNAc in vitro [#3]. By supplying UDP-GlcNAc as the donor for N-linked glycosylation, UAP1 supports cellular proliferation and stress resistance: overexpression raises intracellular UDP-GlcNAc roughly ten-fold and confers resistance to N-linked glycosylation inhibitors, while knockdown re-sensitizes cells and triggers ER stress [#1]. Through this glycosylation-supporting activity UAP1 promotes the aggressive behavior of multiple cancers, where its loss reduces proliferation, migration, invasion, and N-linked glycosylation and shifts cell-cycle and EMT regulators [#6, #7]. Beyond metabolism, UAP1 acts as a protein pyrophosphorylase that directly pyrophosphorylates IRF3 at Ser386 to drive robust type I interferon responses, with Uap1-deficient mice showing impaired antiviral IFN signaling and lethal susceptibility to DNA- and RNA-virus infection [#0]. A de novo p.A229T missense mutation that destabilizes the AGX1 isoform and alters its N-terminal domain conformation links UAP1 to an intellectual disability phenotype [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Before any enzymatic role was assigned, the protein (as SPAG2) was placed at a discrete subcellular structure, establishing its presence as a novel non-intermediate-filament component of the sperm flagellar outer dense fibers.\",\n      \"evidence\": \"Immunofluorescence and electron microscopy of Triton-extracted spermatozoa, plus cDNA library screening\",\n      \"pmids\": [\"9621304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No functional consequence of ODF localization established\",\n        \"Relationship between this structural localization and the later-defined enzymatic activity unexplored\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The core biochemical activity was defined by reconstituting AGX1 as a uridyltransferase that synthesizes UDP-GalNAc and, unexpectedly, accepts deoxynucleotide substrates, mapping its substrate scope.\",\n      \"evidence\": \"In vitro enzymatic assay with systematic nucleotide substrate specificity profiling\",\n      \"pmids\": [\"22595178\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"In vitro substrate promiscuity (dUTP/dTTP) of unknown physiological relevance\",\n        \"No structural basis for substrate selection\",\n        \"Single lab, single method\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"The metabolic output was linked to a cellular phenotype, showing that UAP1-driven UDP-GlcNAc supply sustains N-linked glycosylation and protects cancer cells from glycosylation-inhibitor-induced ER stress.\",\n      \"evidence\": \"siRNA/shRNA knockdown with proliferation and ER stress readouts, UDP-GlcNAc quantification, tissue microarray in prostate cancer cells\",\n      \"pmids\": [\"25241896\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Specific glycoprotein clients not identified\",\n        \"Resistance shown only against glycosylation inhibitors, not general ER stress\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A disease-causing variant was characterized structurally and functionally, establishing that destabilization of the AGX1 isoform via a conformational shift in the N-terminal domain can produce a Mendelian neurodevelopmental phenotype.\",\n      \"evidence\": \"In vitro activity assay, X-ray crystallography, and site-directed mutagenesis of a patient-derived p.A229T variant\",\n      \"pmids\": [\"33098688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Causality at the organismal level not tested (no animal model of the variant)\",\n        \"Mechanistic connection between reduced enzymatic activity and intellectual disability not resolved\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The pro-tumorigenic role was extended beyond prostate to bladder cancer, generalizing UAP1 as a supporter of cancer-cell aggressiveness.\",\n      \"evidence\": \"siRNA knockdown with proliferation, invasion, colony formation, and migration assays in bladder cancer cell lines\",\n      \"pmids\": [\"32650368\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Molecular mediators not defined in this system\",\n        \"No in vivo validation\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A non-canonical catalytic function was discovered: UAP1 acts as a protein pyrophosphorylase on IRF3 Ser386, revealing a direct enzymatic role in innate antiviral immunity distinct from its metabolic activity.\",\n      \"evidence\": \"Biochemical pyrophosphorylase assay, Uap1 knockout mice, viral infection models, IRF3 phosphorylation assays\",\n      \"pmids\": [\"36603579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How the same enzyme partitions between sugar-nucleotide synthesis and protein pyrophosphorylation is unresolved\",\n        \"Substrate scope of the pyrophosphorylase activity beyond IRF3 unknown\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Isoform-specific regulation was placed in a signaling axis, showing that NSUN2/SRSF6-controlled alternative splicing toward AGX2 enhances ABC-transporter glycosylation and stability to drive multidrug resistance.\",\n      \"evidence\": \"NSUN2 knockout cells, MeRIP-seq, proteomics, splicing analysis, glycoprotein staining, and denaturing ubiquitination IP in anaplastic thyroid cancer; CRISPR-Cas9 UAP1 knockout with lectin blots in lung cancer\",\n      \"pmids\": [\"40083919\", \"41452006\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Functional difference between AGX1 and AGX2 at the enzymatic level not fully defined\",\n        \"Direct interaction of AGX2 with ABC transporters not demonstrated\",\n        \"Single lab for the thyroid axis\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how UAP1 mechanistically toggles between its sugar-nucleotide pyrophosphorylase metabolic role, its IRF3 protein-pyrophosphorylase immune role, and its isoform-specific glycosylation-promoting role in disease.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural or regulatory model linking the metabolic and protein-pyrophosphorylase activities\",\n        \"Cellular determinants of AGX1 vs AGX2 functional specialization undefined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 7]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"IRF3\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}